Agendia picks Agilent’s microarrays

Aug. 26, 2003 — Agendia BV of Amsterdam has selected Agilent Technologies Inc.’s custom microarrays as a platform for cancer research, according to a news release.

Agendia is developing the first microarray-based diagnostic test to predict the aggressiveness of breast cancer tumors based on the activity of key genes. The new company, formed by researchers from the Netherlands Cancer Institute, plans to develop microarray tests for various diseases based on gene expression profiles, the release said.

Microarray technologies are not approved for diagnostic use in the United States, so Agendia will handle the microarray analysis of all samples in the Netherlands.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.